Moreover, therapeutic applications to counteract vascular compromise, resolving of oxidative stress in T2DM patients could be achieved by regulating the expression of APOA1 which inhibits oxidative stress42 and RETN (resistin) which regulates the inflammatory response.43 This evidence concerns the gene APOA1 and type 2 diabetes mellitus.